Intuitive Surgical (ISRG) is a publicly traded Healthcare Robots company founded in 1995 and based in Sunnyvale, United States.
No dated funding rounds on file. This company is privately held and may be raising or operating on undisclosed capital.
Intuitive Surgical reported Q3 2026 (quarter ended September 30, 2026) revenue of $3.05 billion, up 22% from $2.51 billion in Q3 2025. GAAP net income attributable to Intuitive was $523 million, or $1.49 per diluted share, down from $704 million, or $1.95, a year earlier. The GAAP results include a $450 million pre-tax litigation charge (SG&A) for the proposed antitrust class action settlement, which is subject to court approval, and a $22 million benefit from IEEPA tariff refunds. Non-GAAP (adjusted) net income was $1.05 billion, or $3.00 per diluted share, versus $867 million, or $2.40, in Q3 2025. Operationally, the company placed 546 da Vinci systems (315 da Vinci 5) and 56 Ion systems; worldwide procedures grew about 15%, and the da Vinci installed base reached 12,094 systems. The company repurchased 7.8 million shares for $2.94 billion, and cash and investments fell to $6.80 billion. Full-year 2026 outlook: da Vinci procedure growth of about 14% to 15%, nearer the midpoint; non-GAAP gross margin of 68.7% to 69.3%, including an estimated 0.9% tariff impact; and non-GAAP operating expense growth of 11% to 13%.
FY2026: da Vinci procedure growth ~14%–15% (nearer midpoint); non-GAAP gross margin 68.7%–69.3%; non-GAAP opex growth 11%–13%

Intuitive Surgical agrees to a $450M settlement of a hospitals' antitrust class action over its da Vinci robot servicing.

FDA clears Medtronic's Hugo surgical robot for upper and lower abdominal general surgery procedures, covering about 3.5 million U.S. surgeries annually.
Indian surgeons perform a beating-heart TECAB procedure using a dual-console, five-arm robotic system.
Intuitive Surgical reports faster da Vinci surgical robot adoption worldwide, per a Simply Wall St stock analysis.
BMO Capital says Intuitive Surgical's ambulatory surgical center robotics opportunity appears meaningful.

Max Super Speciality Hospital in Saket performs India's first day-care bilateral hip replacement using smart AI navigation.
The da Vinci 5 is Intuitive's latest multiport soft-tissue surgical system, designed for minimally invasive procedures across urology, general surgery, gynecology, and other specialties. It adds force feedback instruments that let surgeons sense tissue interaction, along with expanded digital data capture and a more powerful console for surgeon control. Hospitals adopt it to standardize robotic programs on a platform that the company is ramping quickly, with 232 placements in a single recent quarter. It serves surgeons and care teams seeking precision and procedure data.
The da Vinci Xi is the company's widely deployed multiport surgical system, used for complex procedures across urology, gynecology, general surgery, thoracic, and colorectal specialties. Its slim arms and overhead design allow access to multiple quadrants of the body through a few small incisions without repositioning the patient. Xi remains a core installed-base platform for hospitals, supported by a large library of instruments and staff training programs. It helps surgical teams deliver minimally invasive care at scale.
The da Vinci SP is a single-port robotic surgical system that enters the body through one small incision, using a compact instrument design suited to narrow or deep anatomical spaces. It is used in urology, transoral and head-and-neck, and other procedures where a single access point reduces trauma. Surgeons value its ability to reach areas that are difficult with multiport systems. SP has expanded its approved indications and continues to grow in procedure volume.
Ion is Intuitive's endoluminal robotic system designed for minimally invasive biopsy of small peripheral lung nodules through the natural airways. It gives pulmonologists steerable catheter control and integrated imaging so they can reach lesions that are hard to access with conventional bronchoscopy. Hospitals use Ion to support earlier diagnosis of lung cancer. It differentiates the company's portfolio beyond soft-tissue surgery and extends its footprint into diagnostic care.
We don't have a live feed for this company's ATS. Their careers page has every open role.
View all careers ↗